ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Soluble Immune Effector Molecules [I]: Anti-Tumor Necrosis Factor-α Agents)
- MeSH Terms
- Biological Therapy (E02.095); Infectious Disease Medicine (H02.403.429.480); Tumor Necrosis Factor-alpha (D23.529.374.500.800); Tumor Necrosis Factor-alpha (D12.776.467.374.750.626); Tumor Necrosis Factor-alpha (D12.644.276.374.750.626); Tumor Necrosis Factor-alpha (D23.529.374.750.626); Tumor Necrosis Factor-alpha (D12.776.467.972.626); Tumor Necrosis Factor-alpha (D12.644.276.972.626); Tumor Necrosis Factor-alpha (D23.529.972.626)
- Guideline Contact
- Chiara Speziale (guidancedocuments@escmid.org)
- Publication Scope
- treatment
- Guideline Publication Status
- Published
- Languages
- English
- Authors
- ESCMID
- Publication Year
- 2018